Next 10 |
2024-05-16 06:52:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaccinex (NASDAQ: VCNX ) just reported results for the first quarter of 2024. Vaccinex reported earnings per share of -$2.94. The company reported revenue of $104,000....
2024-05-16 06:46:28 ET More on Vaccinex Financial information for Vaccinex Read the full article on Seeking Alpha For further details see: Vaccinex GAAP EPS of -$2.94, revenue of $0.1M
Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pi...
2024-04-26 17:32:28 ET More on Vaccinex Financial information for Vaccinex Read the full article on Seeking Alpha For further details see: Vaccinex files to sell 193,000 shares of common stock for holders
2024-04-17 01:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Soligenix Inc. (SNGX) rose 127.5% to $0.8782 on volume of 62,157,057 shares Trio Petroleum Corp. (TPET) rose 8.0% to $0.5571 on volume of 48,902,033 shares Organovo Holdings Inc. (ONVO) rose 36.3% to $1.3769 on volume of 34,819,187 sh...
2024-04-02 16:21:35 ET More on Vaccinex Financial information for Vaccinex Read the full article on Seeking Alpha For further details see: Vaccinex files to sell 433.5K common shares for holders
2024-04-02 10:09:37 ET More on Vaccinex Financial information for Vaccinex Read the full article on Seeking Alpha For further details see: Vaccinex reports Q4 results
Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024 Company raised $17.9 million of new financing during Q4 2023 and Q1 2024 ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clin...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...
News, Short Squeeze, Breakout and More Instantly...
Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pi...
2024-04-17 01:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...